Tarsus (TARS) Q1 2026 earnings review
Surging Sales and a Clear Path to Profitability
Tarsus delivered an outstanding Q1 2026, driven by the relentless growth of XDEMVY. Net product sales surged 85% YoY to $145.4 million, bolstered by a Direct-to-Consumer (DTC) campaign that is fundamentally shifting eye care practices. While SG&A expenses ballooned to $136.4 million to fund this growth, operating leverage is finally taking hold. Aided by a $16.7 million licensing milestone from China, the company's net loss collapsed to just $7.0 million (from $25.1 million a year ago). Management confidently reaffirmed full-year guidance of $670-$700 million and a U.S. peak sales target of over $2 billion. Tarsus is rapidly evolving from a single-product success story into a cash-rich category creator.
🐂 Bull Case
The massive investment in Direct-to-Consumer advertising is working. High-value website actions jumped 40% sequentially, and nearly half of core eye care professionals (ECPs) are now prescribing XDEMVY weekly.
With Q1 net loss shrinking to $7.0 million and gross margins holding at an elite 94%, Tarsus is on the precipice of sustained profitability without needing to slow its growth engine.
🐻 Bear Case
Despite massive YoY growth, Q1 2026 net product sales ($145.4M) actually declined sequentially from Q4 2025 ($151.7M), highlighting the brand's vulnerability to Q1 seasonality and deductible resets.
Operating expenses remain extremely high. Tarsus spent $136.4M in SG&A in a single quarter. Any future disruption in revenue growth would immediately expose this bloated cost structure.
⚖️ Verdict: 🟢
Bullish. Tarsus is executing a flawless launch. The sequential product sales dip is a known seasonal factor, heavily outweighed by an 85% YoY growth rate and a rapidly shrinking cash burn.
Key Themes
DTC Campaign Shifts Prescribing Habits
Tarsus's aggressive Direct-to-Consumer strategy is generating phenomenal ROI. High-value actions on XDEMVY.com grew 40% quarter-over-quarter. More importantly, this patient activation is converting doctors: nearly half of core ECPs are now prescribing XDEMVY on a weekly basis, effectively shifting Demodex blepharitis treatment from a niche intervention to a standard of care.
Category Creation Pipeline Validated
Management is leveraging XDEMVY's cash flow to fund specific technological innovations in untreated markets. Tarsus initiated 'Calliope', a Phase 2 trial for TP-05—a novel oral prophylactic designed to kill ticks and prevent Lyme disease before transmission. Concurrently, TP-04 (sterile ophthalmic gel) for ocular rosacea remains on track. Topline data for both is expected in H1 2027, transforming Tarsus into a diversified biotech.
International Milestones Hit the P&L
Global expansion is officially generating cash. Partner Grand Pharmaceuticals secured regulatory approval for XDEMVY in China, triggering a $15.0 million milestone payment (recorded as $16.7M gross revenue due to a $1.7M tax withholding). Meanwhile, the European preservative-free formulation is completing stability work in 2026, setting up the next leg of international growth.
The Q1 Sequential Reality Check
While YoY growth is staggering, a closer look contradicts the straight-line hyper-growth narrative. XDEMVY net product sales decelerated sequentially, dropping from $151.7 million in 25Q4 to $145.4 million in 26Q1. This underscores that XDEMVY is still highly dependent on new prescriptions (NRx) rather than recurring refills.
Macro Exposure: Deductibles & Seasonality
The sequential product sales decline highlights Tarsus's exposure to macro healthcare economics. Because XDEMVY relies on NRx and DTC activation, it is highly sensitive to Q1 insurance deductible resets, severe winter weather keeping patients from clinics, and general consumer spending caution early in the year.
Escalating Commercial Costs
The cost of creating a category is steep. SG&A expenses rocketed from $85.0M in 25Q1 to $136.4M in 26Q1. The company is actively adding 20 new Key Account Leaders by Q3 2026. Tarsus is winning the revenue race, but it must maintain relentless top-line momentum to outrun its heavy commercial infrastructure.
Other KPIs
Stable. Gross margins remained elite and practically unchanged from 93% in 25Q1. Cost of sales ($9.4M) consists primarily of manufacturing, royalties, and milestone amortizations, proving XDEMVY's massive profitability profile at the unit economics level.
Extremely healthy. While total cash and marketable securities dipped slightly from FY25, the shrinking net loss ($7.0M in Q1) means Tarsus has a massive runway. They do not need to raise capital to reach sustained profitability or fund Phase 2 pipeline trials.
Guidance
Decelerating on a percentage basis but accelerating in absolute dollars. Achieving the midpoint ($685M) implies a 52% YoY increase over FY25's $451.4 million. The maintained guidance shows confidence that momentum will rebound following the Q1 seasonal dip.
Management reaffirmed their massive long-term target, leaning heavily on the fact that the Demodex blepharitis market is vast and vastly underpenetrated, validating their 'category creator' thesis.
Management committed to a concrete timeline for their next growth legs, expecting Phase 2 topline data for both TP-04 (Ocular Rosacea) and TP-05 (Lyme Disease prevention) in the first half of 2027.
Key Questions
Refill Dynamics
Given the sequential dip in Q1 product sales, can you update us on the current annualized retreatment/refill rate? Are we progressing toward the 20% steady-state target, or is the brand remaining almost entirely reliant on NRx?
SG&A Ceiling
SG&A reached $136.4 million this quarter. As the DTC campaign matures and the 20 new Key Account Leaders are onboarded by Q3, where do you see quarterly SG&A run-rates stabilizing?
European Go-To-Market Strategy
With the preservative-free stability work completing in 2026, what is the latest thinking on commercializing in Europe? Will Tarsus build its own footprint, or are you actively seeking a licensing partner similar to the Grand Pharma deal in China?